Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML

Five years ago Otsuka swept in and scooped up California-based Astex for $886 million, determined to get its hands on their promising leukemia drug SGI-110 as it plugged the operations into its global R&D ops.